Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Revenue
Immunoprecise Antibodies Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Revenue
CA$17.9m
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Revenue
$38m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Revenue
CA$4.9m
|
CAGR 3-Years
239%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
62%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Revenue
CA$353.7k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
Innovotech Inc
XTSX:IOT
|
Revenue
CA$1.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
See Also
What is Immunoprecise Antibodies Ltd's Revenue?
Revenue
17.9m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Revenue amounts to 17.9m CAD.
What is Immunoprecise Antibodies Ltd's Revenue growth rate?
Revenue CAGR 3Y
49%
Over the last year, the Revenue growth was 27%. The average annual Revenue growth rates for Immunoprecise Antibodies Ltd have been 49% over the past three years .